Implications of cancer evolution for drug development

被引:27
|
作者
Turajlic, Samra [1 ,2 ,3 ]
Swanton, Charles [1 ,4 ]
机构
[1] Francis Crick Inst, Translat Canc Therapeut Lab, 1 Midland Rd, London NW1 1AT, England
[2] Royal Marsden Hosp, Renal Unit, London SW3 6JJ, England
[3] Royal Marsden Hosp, Skin Unit, London SW3 6JJ, England
[4] UCL, Canc Res UK Lung Canc Ctr Excellence, Canc Inst, Paul OGorman Bldg,72 Huntley St, London WC1E 6BT, England
关键词
HETEROGENEITY; RESISTANCE;
D O I
10.1038/nrd.2017.78
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Tumour evolution, which results in the existence of multiple distinct populations of cancer cells within the same tumour and the same patient, is increasingly appreciated to have a key role in drug resistance. In this article, we discuss the implications for drug development, including approaches to reduce the likelihood of the emergence of drug resistance.
引用
收藏
页码:441 / 442
页数:2
相关论文
共 50 条